ByteDance-Spun-Off Anew Labs Closes $290M First Round at $1.5B Valuation
The AMW Read
A new, well-capitalized ByteDance-backed entrant plus data showing China's AI drug discovery capital concentrating in a handful of mega-rounds signals a segment-level shift toward late-stage capital discipline.
ByteDance-Spun-Off Anew Labs Closes $290M First Round at $1.5B Valuation
Anew Labs (上海新生探途), an AI-driven drug discovery company spun off from ByteDance and based in Shanghai's Yangpu district, has closed an oversubscribed $290 million first-round financing at a $1.5 billion post-money valuation. The round was led by HongShan (formerly Sequoia China), IDG Capital and Hillhouse Ventures, with 5Y Capital co-leading; Banyan Capital, Primavera Capital and Boyu Capital also participated. Sino Biopharmaceutical joined as a strategic investor alongside the state-backed Shanghai Future Industry Fund.
The deal sits inside a broader financing surge in China's AI drug discovery sector: 57 investments across 44 companies in the first nine months of 2026, with disclosed funding of RMB 15.77 billion (~$2.2 billion) — more than 2023, 2024 and 2025 combined. Deal count rose only modestly, but capital concentrated at the top: the four largest 2026 rounds, including Anew Labs's raise and Hua Shen Zhi Yao's $787 million Series B after a Sanofi partnership worth up to $2.56 billion in potential milestones, account for roughly 60% of total sector financing.
For investors and operators, mega-round qualifying criteria are narrowing rather than the sector simply heating up: pharma or big-tech pedigree, an existing multinational licensing deal, and a Shanghai or Beijing base (together 44% of China's 164 AI drug discovery firms) are becoming prerequisites. Industrial capital, local state funds, and — in peer rounds — sovereign vehicles like the Abu Dhabi Investment Authority and Temasek's Duxin Capital point to non-traditional biotech LPs underwriting the bet at scale, worth tracking when structuring partnerships or follow-on rounds.
